Anti-N-sulfated heparan sulfate Purified

Anti-N-sulfated heparan sulfate Purified
Regulatory status
RUO
Antigen
N-sulfated heparan sulfate
Clone
HepSS-1
Format
Purified
Reactivity
Broad
Application
IP, IHC, WB, FC (QC tested), ICC
Variant
0.1 mg
11-821-C100
In stock
Variant
0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Mouse IgM
Specificity
The mouse monoclonal antibody HepSS-1 (also known as HepSS1) recognizes N-sulfated heparan sulfate present in many species.
Application
IP, IHC, WB, FC (QC tested), ICC
Application details
Flow cytometry: Recommended dilution: 1-5 μg/ml.
Reactivity
Broad
Immunogen
MethA murine fibrosarcoma
Other names
N-sulfo-rich heparan sulfate
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Tris buffered saline (TBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

Product specific references:

Kure S, Yoshie O: A syngeneic monoclonal antibody to murine Meth-A sarcoma (HepSS-1) recognizes heparan sulfate glycosaminoglycan (HS-GAG): cell density and transformation dependent alteration in cell surface HS-GAG defined by HepSS-1. J Immunol. 1986 Dec 15;137(12):3900-8.
PubMed
van den Born J, Salmivirta K, Henttinen T, Ostman N, Ishimaru T, Miyaura S, Yoshida K, Salmivirta M: Novel heparan sulfate structures revealed by monoclonal antibodies. J Biol Chem. 2005 May 27;280(21):20516-23.
PubMed
Lipscombe RJ, Nakhoul AM, Sanderson CJ, Coombe DR: Interleukin-5 binds to heparin/heparan sulfate. A model for an interaction with extracellular matrix. J Leukoc Biol. 1998 Mar;63(3):342-50.
PubMed
Crim RL, Audet SA, Feldman SA, Mostowski HS, Beeler JA: Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity. J Virol. 2007 Jan;81(1):261-71. Epub 2006 Oct 18.
PubMed
Chung JS, Shiue LH, Duvic M, Pandya A, Cruz PD Jr, Ariizumi K: Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Blood. 2011 Mar 24;117(12):3382-90.
PubMed
Kure S, Yoshie O, Aso H: Metastatic potential of murine B16 melanoma correlates with reduced surface heparan sulfate glycosaminoglycan. Jpn J Cancer Res. 1987 Nov;78(11):1238-45.
PubMed
Mii Y, Yamamoto T, Takada R, Mizumoto S, Matsuyama M, Yamada S, Takada S, Taira M: Roles of two types of heparan sulfate clusters in Wnt distribution and signaling in Xenopus. Nat Commun. 2017 Dec 7;8(1):1973.
PubMed
Variant
0.1 mg
11-821-C100
In stock
Variant
0.1 mg
11-261-C100
In stock